Hepatitis C Drugs Market trend, outlook 2025
Hepatitis C drug market Taxonomy
By Drug Class
Hepatitis C Virus Protease Inhibitor
Nucleoside/tide Polymerase Inhibitors
Non-Nucleoside Polymerase Inhibitors
By Distribution Channel
Request for TOC : https://www.coherentmarketinsights.com/ongoing-insight/toc/1489
Hepatitis C drug market Driver
According to the World Health Organization (WHO), in 2017, around 71 million people were infected by chronic hepatitis C worldwide. Furthermore, WHO considers Eastern Mediterranean and European regions to be the most affected regions with the prevalence rate of 2.3% and 1.5% respectively. According to the Centers for Disease Control and Prevention, around 2.7 million to 3.9 million people in the U.S. suffer from hepatitis C. This increasing prevalence of hepatitis C will drive growth of hepatitis C drug market. Furthermore, this blood- borne virus is easily transmitted by sharing injection equipment, transfusion of infectious blood, sexually or from infected mother to infant, which will further propel growth of hepatitis C drug market.
The governmental initiatives for patients to receive expanded drug coverage is also expected to drive growth of the market. For instance, in 2018, the Ministry of Health and Long-Term Care of Ontario announced that all patients are eligible for Ontario Drug Benefit (ODP) irrespective of severity of their disease. In the same year, Thunder Bay group, HIV / AIDS / hepatitis C education and support services provider, expanded its access to medicines, as a result of successful negotiations between the provinces and drug manufacturers.
There are significant number of drugs available for Hepatitis C over the past few years and is expected to increase over the forecast period due to large number of drugs in pipeline. Hepatitis C drug market is revolutionized by direct acting antivirals (DAAs), which aid in the development of highly effective, INF-free hepatitis C drug regimen in contrast to standard treatment. The pipeline consists of dual as well as triple DDA combinational therapy against hepatitis C virus. A combination of drugs is more effective for the treatment of hepatitis C as compared to single regimen. For instance, in 2016, Gilead submitted a new drug application to the U.S. FDA for the fixed-dose combination SOF/VEL/voxilaprevir for treatment of HCV genotypes 1–6. Moreover, in January 2017, EMA granted assessment of SOF/VEL/voxilaprevir combination. Furthermore, in 2017, the U.S. FDA approved AbbVie’s Mavyret, a combination of glecaprevir and pibrentasvir for the treatment of hepatitis C. Hepatitis C drug market is hindered due to high medication cost and denial for Medicaid patients.
Hepatitis C Drug Market
The major players in hepatitis C drug market include Merck & Co. Inc., Vertex Pharmaceuticals, Roche, Gilead Sciences Inc., AbbVie Inc., Johnson & Johnson, and Bristol-Myers Squibb.
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Hepatitis C Drugs Market trend, outlook 2025 here
News-ID: 1102580 • Views: 577
More Releases from Coherent Market Insights - Pharmaceutical Industry
Radiopharmaceuticals in Nuclear Medicine Market Advancements to Watch Out For 20 …
Coherent Market Insights released a new market study on 2018-2026 Radiopharmaceuticals Market with 100+ market data Tables, Pie Chat, Graphs & Figures spread through Pages and easy to understand detailed analysis. At present, the market is developing its presence. The Research report presents a complete assessment of the Market and contains a future trend, current growth factors, attentive opinions, facts, and industry validated market data. Ask For Sample Copy of Research
Outsourced Drug Discovery Market: Latest Advancements & Market Outlook 2019 to 2 …
Outsourced drug discovery is a contract-based process, which is conducted by the contract research organizations (CRO) and contract manufacturing organization (CMO). Contract research organization provides support to pharmaceutical, biotechnology, and medical device industries for drug discovery and development. CRO facilitates the various services such as biopharmaceutical development, biologic assay development, preclinical research, clinical trials, and pharmacovigilance, for drug discovery and development. Ask For a Sample Copy of This Business Report @
Cannabis Testing Services Market: New Business Opportunities and Investment Rese …
Cannabis market is highly influenced by rigorous legalization efforts, which are aiming for approval of cannabis for medicinal or recreational purpose. Various governments and regulatory authorities are taking efforts to legalize cannabis, owing to its medicinal benefits. Moreover, commercialization of cannabis-based products under the legalized standards require successful cannabis testing, which further results in lucrative growth opportunity for market players. Ask For a Sample Copy of This Business Report @ https://www.coherentmarketinsights.com/insight/request-sample/2976 Market
Global Myelodysplastic Syndrome (MDS) Treatment Market Balenced To Reach Insigni …
Myelodysplastic syndrome (MDS) is a disorder, which affects the bone marrow and produces immature blood cells. Bone marrow failure leads to lowering the levels of healthy blood cells circulation in the bloodstream. According to Seattle Cancer Care Alliance, around 80%-85% of people with MDS have more cells in their bone marrow than healthy people. According to National Organization for Rare Disorders, MDS deteriorates into a form of cancer in around
More Releases for Hepatitis
Hepatitis E Therapeutics Pipeline Analysis 2018
Hepatitis E is a liver disease caused by infection due to a virus known as hepatitis E virus (HEV). This disease can cause swelling in liver. Some of the common symptoms are mild fever, feeling of tiredness, feeling sick to stomach, and belly pain. Download the sample report at: https://www.pharmaproff.com/request-sample/1029 The World Health Organization (WHO) estimates released in 2018 stated that, every year, an estimated 20 million HEV infections worldwide, leading to
Hepatitis Drugs Market Opportunity Assessment Study
The global hepatitis drugs market is growing due to increasing incidences of hepatitis and increasing support from government organizations. In addition, the growing geriatric population, and increasing R&D investments on hepatitis research and drug discovery are also driving the growth of the global hepatitis drugs market. Access Detailed Report Summary: https://www.psmarketresearch.com/market-analysis/hepatitis-drugs-market The increasing incidences of various types of hepatitis, such as hepatitis B, and hepatitis C are playing a pivotal role in
Global Hepatitis A Vaccine Sales Market Report
In this report, the global Hepatitis A Vaccine market is valued at USD XX million in 2017 and is expected to reach USD XX million by the end of 2025, growing at a CAGR of XX% between 2017 and 2025. Geographically, this report split global into several key Regions, with sales (K Units), revenue (Million USD), market share and growth rate of Hepatitis A Vaccine for these regions, from 2013
Hepatitis B Vaccines Market Growth Analysis 2021
Hepatitis B refers to an infectious disease that is caused by hepatitis B virus. Symptoms of this disease are not visible in initial stages and develop after few weeks only. Hepatitis B virus is transmitted by exposure to infectious blood or body fluids of an infected person. This disease may even occur from the birth. Hepatitis B may be caused by blood transfusions, healthcare setting, sharing razors and dialysis. Hepatitis
Hepatitis Drug Market Hepatitis Drug Clinical Pipeline Report 2023
For Report Sample Contact: email@example.com or +91-11-47067990 Report Table of Contents 1. Introduction to Hepatitis Disease 1.1 Prologue 1.1.1 History of Hepatitis 1.1.2 Causes of Hepatitis Disease 1.2 Types of Viruses which are Responsible for Hepatitis Disease 2. Global Prevalence of Hepatitis Infection 3. Available Drug Classes for Hepatitis Disease Treatment 3.1 Interferon Alfa Therapy 3.2 Protease Inhibitors Therapy 3.3 Polymerase
Global Hepatitis C Drug Sales Market 2017
In this report, the Global Hepatitis C Drug Market 2017 is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split global into several key Regions, with sales (K Units), revenue (Million USD), market share and growth rate of Hepatitis C Drug for these regions, from 2012